Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/184795
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Campo DC Valor Lengua/Idioma
dc.contributor.authorRodríguez-Carrio, Javieres_ES
dc.contributor.authorAlperi-López, Mercedeses_ES
dc.contributor.authorLópez-Mejías, Raqueles_ES
dc.contributor.authorLópez, Patriciaes_ES
dc.contributor.authorBallina García, Francisco Javieres_ES
dc.contributor.authorAbal, Franciscoes_ES
dc.contributor.authorGonzález-Gay, M. A.es_ES
dc.contributor.authorSuárez, Anaes_ES
dc.date.accessioned2019-06-25T09:46:14Z-
dc.date.available2019-06-25T09:46:14Z-
dc.date.issued2016-09-22-
dc.identifier.citationClinical Science 130 (21): 1889-1899 (2016)es_ES
dc.identifier.issn0143-5221-
dc.identifier.urihttp://hdl.handle.net/10261/184795-
dc.description.abstractTraditional and non-traditional cardiovascular (CV) risk factors underlie CV disease occurrence in rheumatoid arthritis (RA). Recently, a functional impairment of high-density lipoprotein (HDL) has been observed. Although the actual players are unknown, anti-HDLs were associated with altered lipid profile, decreased paraoxonase 1 (PON1) activity and CV disease in RA. Therefore, we aimed to evaluate whether the presence of antibodies against PON1 may be involved in this scenario. IgG anti-PON1 antibodies were quantified by ELISA in serum samples from 212 RA patients, 175 healthy controls (HC) and 54 subjects with traditional CV risk factors (CVR). A subgroup of 13 RA patients was prospectively followed upon tumour necrosis factor-α (TNFα) blockade. Serum PON1 activity, nitric oxide (NO) and total antioxidant capacity (TAC) were measured. Interferon-γ (IFNγ), interleukin 8 (IL-8), monocyte chemotactic protein 1 (MCP-1), vascular endothelial growth factor (VEGF), soluble intercellular adhesion molecule (sICAM) and TNFα serum levels were assessed by immunoassays. PON1 rs662 (Q > R) status was studied by reverse transcription (RT)–PCR. IgG anti-PON1 antibodies are increased in RA patients compared with HC (P<0.0001) and CVR subjects (P<0.001), even after correcting for total IgG levels. Although no associations with lipid profile were found, a positive correlation with Health Assessment Questionnaire (HAQ) was observed (r=0.215, P=0.004). Anti-PON1 antibodies were associated with PON1 activity, NO and TAC, a rs662-mediated gene-dosage effect being found. Similarly, anti-PON1 antibodies were associated with sICAM serum levels in univariate and multivariate models. Finally, these antibodies were not affected by TNFα blockade. Anti-PON1 antibodies can be responsible for PON1 impairment in RA patients, with a potential impact on biomarkers of oxidative status and endothelial activation. A gene–environment interaction of rs662 variants is supported.es_ES
dc.description.sponsorshipThis work was supported by the European Union FEDER funds and ‘Fondo de Investigación Sanitaria’ (ISCIII, Health Ministry, Spain) [grant numbers PI12/00523, PI12/00060 and PI15/00525]; the RETICS Programs (ISCIII, Health Ministry, Spain) [grant number RD12/0009 (RIER)]; the Spanish Society for Rheumatology (SER) [travel grant (to J.R.-C.)]; the FICYT (Fundación para el fomento en Asturias de la Investigación Científica aplicada y la Tecnología) [grant number GRUPIN14-043 (to J.R.-C.)]; and the RETICS Program (RIER) [grant number RD12/0009/0013 (to R.L.M.)]es_ES
dc.language.isoenges_ES
dc.publisherPortland Presses_ES
dc.rightsclosedAccesses_ES
dc.subjectAnti-paraoxonase 1 antibodieses_ES
dc.subjectCardiovascular diseasees_ES
dc.subjectHigh-density lipoproteinses_ES
dc.subjectParaoxonasees_ES
dc.subjectRheumatoid arthritises_ES
dc.titleAntibodies to paraoxonase 1 are associated with oxidant status and endothelial activation in rheumatoid arthritises_ES
dc.typeartículoes_ES
dc.identifier.doi10.1042/CS20160374-
dc.description.peerreviewedPeer reviewedes_ES
dc.relation.publisherversionhttp://dx.doi.org/10.1042/CS20160374es_ES
dc.identifier.e-issn1470-8736-
dc.contributor.funderEuropean Commissiones_ES
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderSociedad Española de Reumatologíaes_ES
dc.contributor.funderFundación para el Fomento en Asturias de la Investigación Científica Aplicada y la Tecnologíaes_ES
dc.relation.csices_ES
oprm.item.hasRevisionno ko 0 false*
dc.identifier.funderhttp://dx.doi.org/10.13039/501100004587es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100008430es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100000780es_ES
dc.contributor.orcidRodríguez-Carrio, Javier [0000-0002-0011-5102]es_ES
dc.contributor.orcidLópez, Patricia [0000-0002-1843-0653]es_ES
dc.contributor.orcidSuárez, Ana [0000-0002-4452-7539]es_ES
dc.type.coarhttp://purl.org/coar/resource_type/c_6501es_ES
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeartículo-
item.fulltextNo Fulltext-
item.languageiso639-1en-
Aparece en las colecciones: (IPLA) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato
accesoRestringido.pdf15,35 kBAdobe PDFVista previa
Visualizar/Abrir
Show simple item record

CORE Recommender

SCOPUSTM   
Citations

14
checked on 24-abr-2024

WEB OF SCIENCETM
Citations

14
checked on 25-feb-2024

Page view(s)

280
checked on 26-abr-2024

Download(s)

34
checked on 26-abr-2024

Google ScholarTM

Check

Altmetric

Altmetric


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.